Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial

PURPOSE: To assess the effects of ruxolitinib on symptom burden and quality of life (QoL) and to evaluate the ability of the modified Myelofibrosis Symptom Assessment Form (MFSAF) v2.0 to measure meaningful changes in myelofibrosis-related symptoms in patients with myelofibrosis. PATIENTS AND METHOD...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Mesa, Ruben A., Gotlib, Jason, Gupta, Vikas, Catalano, John V., Deininger, Michael W., Shields, Alan L., Miller, Carole B., Silver, Richard T., Talpaz, Moshe, Winton, Elliott F., Harvey, Jimmie H., Hare, Thomas, Erickson-Viitanen, Susan, Sun, William, Sandor, Victor, Levy, Richard S., Kantarjian, Hagop M., Verstovsek, Srdan
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2013
Matèries:
ORIGINAL REPORTS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4979167/
https://ncbi.nlm.nih.gov/pubmed/23423753
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.44.4489
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars